Literature DB >> 25092743

The democratization of the oncogene.

Anh T Le1, Robert C Doebele2.   

Abstract

The identification of novel, oncogenic gene rearrangements in inflammatory myofibroblastic tumor demonstrates the potential of next-generation sequencing (NGS) platforms for the detection of therapeutically relevant oncogenes across multiple tumor types, but raises significant questions relating to the investigation of targeted therapies in this new era of widespread NGS testing. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25092743      PMCID: PMC4123669          DOI: 10.1158/2159-8290.CD-14-0628

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  10 in total

1.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Authors:  Anirudh Prahallad; Chong Sun; Sidong Huang; Federica Di Nicolantonio; Ramon Salazar; Davide Zecchin; Roderick L Beijersbergen; Alberto Bardelli; René Bernards
Journal:  Nature       Date:  2012-01-26       Impact factor: 49.962

2.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

Authors:  James E Butrynski; David R D'Adamo; Jason L Hornick; Paola Dal Cin; Cristina R Antonescu; Suresh C Jhanwar; Marc Ladanyi; Marzia Capelletti; Scott J Rodig; Nikhil Ramaiya; Eunice L Kwak; Jeffrey W Clark; Keith D Wilner; James G Christensen; Pasi A Jänne; Robert G Maki; George D Demetri; Geoffrey I Shapiro
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

3.  Kinase fusions are frequent in Spitz tumours and spitzoid melanomas.

Authors:  Thomas Wiesner; Jie He; Roman Yelensky; Rosaura Esteve-Puig; Thomas Botton; Iwei Yeh; Doron Lipson; Geoff Otto; Kristina Brennan; Rajmohan Murali; Maria Garrido; Vincent A Miller; Jeffrey S Ross; Michael F Berger; Alyssa Sparatta; Gabriele Palmedo; Lorenzo Cerroni; Klaus J Busam; Heinz Kutzner; Maureen T Cronin; Philip J Stephens; Boris C Bastian
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

4.  Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21).

Authors:  Alain Charest; Keara Lane; Kevin McMahon; Julie Park; Elizabeth Preisinger; Helen Conroy; David Housman
Journal:  Genes Chromosomes Cancer       Date:  2003-05       Impact factor: 5.006

Review 5.  Molecular pathways: ROS1 fusion proteins in cancer.

Authors:  Kurtis D Davies; Robert C Doebele
Journal:  Clin Cancer Res       Date:  2013-05-29       Impact factor: 12.531

Review 6.  Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review.

Authors:  N Savage; T I George; J Gotlib
Journal:  Int J Lab Hematol       Date:  2013-03-13       Impact factor: 2.877

7.  ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.

Authors:  Dara L Aisner; Teresa T Nguyen; Diego D Paskulin; Anh T Le; Jerry Haney; Nathan Schulte; Fiona Chionh; Jenny Hardingham; John Mariadason; Niall Tebbutt; Robert C Doebele; Andrew J Weickhardt; Marileila Varella-Garcia
Journal:  Mol Cancer Res       Date:  2013-12-02       Impact factor: 5.852

8.  Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.

Authors:  Christine M Lovly; Abha Gupta; Doron Lipson; Geoff Otto; Tina Brennan; Catherine T Chung; Scott C Borinstein; Jeffrey S Ross; Philip J Stephens; Vincent A Miller; Cheryl M Coffin
Journal:  Cancer Discov       Date:  2014-05-29       Impact factor: 39.397

9.  Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Authors:  Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

10.  Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours.

Authors:  Ashley H Birch; Suzanna L Arcand; Kathleen K Oros; Kurosh Rahimi; A Kevin Watters; Diane Provencher; Celia M Greenwood; Anne-Marie Mes-Masson; Patricia N Tonin
Journal:  PLoS One       Date:  2011-12-06       Impact factor: 3.240

  10 in total
  5 in total

1.  EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.

Authors:  Aria Vaishnavi; Laura Schubert; Uwe Rix; Lindsay A Marek; Anh T Le; Stephen B Keysar; Magdalena J Glogowska; Matthew A Smith; Severine Kako; Natalia J Sumi; Kurtis D Davies; Kathryn E Ware; Marileila Varella-Garcia; Eric B Haura; Antonio Jimeno; Lynn E Heasley; Dara L Aisner; Robert C Doebele
Journal:  Cancer Res       Date:  2017-04-20       Impact factor: 12.701

Review 2.  The hallmarks of premalignant conditions: a molecular basis for cancer prevention.

Authors:  Bríd M Ryan; Jessica M Faupel-Badger
Journal:  Semin Oncol       Date:  2015-09-08       Impact factor: 4.929

3.  An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.

Authors:  Rafal Dziadziuszko; Anh T Le; Anna Wrona; Jacek Jassem; D Ross Camidge; Marileila Varella-Garcia; Dara L Aisner; Robert C Doebele
Journal:  J Thorac Oncol       Date:  2016-04-09       Impact factor: 15.609

Review 4.  The minority report: targeting the rare oncogenes in NSCLC.

Authors:  Caroline E McCoach; Robert C Doebele
Journal:  Curr Treat Options Oncol       Date:  2014-12

5.  Activation of RAS family members confers resistance to ROS1 targeting drugs.

Authors:  Marilisa Cargnelutti; Simona Corso; Margherita Pergolizzi; Laurence Mévellec; Dara L Aisner; Rafal Dziadziuszko; Marileila Varella-Garcia; Paolo M Comoglio; Robert C Doebele; Jorge Vialard; Silvia Giordano
Journal:  Oncotarget       Date:  2015-03-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.